Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Skin Neoplasms 1Skin Diseases 1Breast Neoplasms 1

Interventions

pembrolizumab 2Interleukin-2 2Biopsy 2montanide ISA 51 1liposomal doxorubicin 1cemiplimab 1cc-486 1brodalumab 1atezolizumab 1SUB1 protein, human 1Radiotherapy, Image-Guided 1Quality of Life 1Psychiatric Rehabilitation 1Poly I-C 1Patient Reported Outcome Measures 1Observation 1Molecular Diagnostic Techniques 1Mass Screening 1Injections 1Immunotherapy 1Immunohistochemistry 1IT-101 1Genetic Profile 1Floderm topical cream 1Drug Therapy 1Camptothecin 1CALAA-01 1Biological Therapy 1Azacitidine 12-cyclohexylidenhydrazo-4-phenyl-thiazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Floderm topical cream × Breast × Clear all
NCT04138342 2019-10-24

Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer

Al-Azhar University

Phase 1 Unknown
30 enrolled
BreastDermatologic

Breast Neoplasms, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡